Vaxart Inc (VXRT)

2.100
-0.080(-3.67%)
After Hours
2.080
-0.020(-0.952%)
- Real-time Data
  • Volume:
    4,172,505
  • Day's Range:
    2.015 - 2.160
  • 52 wk Range:
    2.020 - 8.490
Trading near 52-week Low

Vaxart has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

VXRT Overview

Prev. Close
2.18
Day's Range
2.015-2.16
Revenue
465K
Open
2.14
52 wk Range
2.02-8.49
EPS
-0.741
Volume
4,172,505
Market Cap
265.66M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,594,853
P/E Ratio
-4.54
Beta
-3.14
1-Year Change
-75.15%
Shares Outstanding
126,506,309
Next Earnings Date
Nov 16, 2022
What is your sentiment on Vaxart?
or
Market is currently closed. Voting is open during market hours.

Vaxart Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Vaxart Inc Analysis

Vaxart Inc Company Profile

Vaxart Inc Company Profile

Employees
110

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryNeutralBuyStrong SellStrong SellStrong Sell
  • Bbgck
    0
    • Why did this coming to $4 from $16? Is there any hope?
      1
      • No
        0
    • Any longterm hope on this?
      0
      • Is it sell or hold at 15.13
        1
        • its a sell, because it was around 38 cents when i bought it, and now it will keep going down foe a wgile before it picks up
          1
      • 16$ is good entry. Buy and hold. got it at 15. By december , will reach over 100$
        0
        • THis stock will soar to $100 and over. Will follow NVAX
          0
          • Sheres the info on this?
            0
        • Is 16$ a good entry?
          0
          • this is a 100$ stock
            0
            • NIAID creates new COVID-19 drug and vaccine trial network through Trump's Warp Speed programby Ben Adams |  Jul 9, 2020 7:55am
              0
              • "Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates
                0